Ulcers carrageenan

A group from La Jolla Pharmaceuticals has released data on their novel hydrazines in recent scientific [20,59,60] and patent literature [61,62], A series of arylallyl hydrazines (e.g., 8 and 9) were shown to be potent, irreversible inhibitors of rat and human SSAO/VAP-1 [59]. LJP-1207 (8, IC50 = 2nM, human) was evaluated in a series of in vivo inflammation models. Significant efficacy was observed in a mouse ulcerative colitis, mouse LPS-induced septic shock, and the rat carrageenan foot models [20], in a mouse model that resembles human multiple sclerosis [63], and in a transient forebrain ischemia model in estrogen-treated ovariectomized female rats [60]. 

Ford et al. (1995) assessed the intestinal permeability changes induced by non-steroidal antiinflammatory drugs in the rat. A subcutaneous air pouch was formed by injection of 10 ml sterile air prior to the experiment. Five ml of a 0.4 % carrageenan solution were injected into the pouch simultaneously with a subcutaneous injection of various doses of the non-steroidal anti-inflammatory drug and the rats allowed access to food. After various time intervals, different markers were given orally and urine collected for 5 h. The use of [51Cr]-EDTA as marker was found to be the most sensitive and reproducible method. The results correlated well with data of ulcer formation. 

Emerson, L. and Kerkut, G. A. (1974). Effect of oral administration of degraded carrageenan on the induction of gastric ulcers in rats treated with glucocorticoids. /. Comp. Pathol. 84 (2), 151-159. 

Grasso, P., Sharratt, M., Carpanini, F.M. Gangolli, S.D. (1973) Studies on carrageenan and large-bowel ulceration in mammals. Food Cosmet. Toxicol. 11(4), 555-564. 

---